StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Trading Down 6.5 %

DBVT stock opened at $4.87 on Friday. The stock has a market capitalization of $100.17 million, a P/E ratio of -1.08 and a beta of 0.71. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $8.32. The firm has a 50-day moving average price of $4.37 and a 200-day moving average price of $3.82.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.